hypoxia; apoptosis; daunomycin; colorectal cancer; Akt; Bad
Abstract :
[en] Hypoxia, a common feature of solid tumors, is a direct stress that triggers apoptosis in many cell types. Poor or irregular tumor vascularization also leads to a decreased drug diffusion and cancer cells distant from blood vessels (hypoxic cells) are exposed to low drug concentrations. In this report, we show that low daunomycin concentrations protect HCT116 colorectal cancer cells from hypoxia-induced apoptosis. While hypoxia induced p53 accumulation without expression of its responsive genes (bax and p21), daunomycin treatment restored p53 transactivation activity and cell cycle progression. We also demonstrated a role for Akt activation in daunomycin-induced protection through phosphorylation and inactivation of the Bcl-2 family proapoptotic factor Bad. Our data therefore suggest that chemotherapy could possibly, because of low concentrations in poorly vascularized tumors, protect cancer cells from hypoxia-induced cytotoxicity.
Achison M and Hupp TR. (2003). Oncogene, 22, 3431-3440.
Ashcroft M, Taya Y and Vousden KH. (2000). Mol. Cell. Biol., 20, 3224-3233.
Brown JM and Giaccia AJ. (1998). Cancer Res., 58, 1408-1416.
Chao W, Matsui T, Novikov MS, Tao J, Li L, Liu H, Ahn Y and Rosenzweig A. (2003). J. Gene Med., 5, 277-286.
Clark AS, West K, Streicher S and Dennis PA. (2002). Mol. Cancer Ther., 1, 707-717.
Datta SR, Brunet A and Greenberg ME. (1999). Genes Dev., 13, 2905-2927.
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME. (1997). Cell, 91, 231-241.
del Peso L, Gonzalez-Garcia M, Page C, Herrerra R and Nunez G. (1997). Science, 278, 687-689.
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW and Giaccia AJ. (1996). Nature, 379, 88-91.
Graeber TG, Peterson JF, Tsai M, Monica K, Fornace Jr AJ and Giaccia AJ. (1994). Mol. Cell. Biol., 14, 6264-6277.
Hirai K, Hayashi T, Chan PH, Zeng J, Yang GY, Basus VJ, James TL and Litt L. (2004). Brain Res. Mol. Brain Res., 124, 51-61.
Kim CY, Tsai MH, Osmanian C, Graeber TG, Lee JE, Giffard RG, DiPaolo JA, Peehl DM and Giaccia AJ. (1997). Cancer Res., 57, 4200-4204.
Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW, Kastan M and Giaccia A. (2001). Mol. Cell. Biol., 21, 1297-1310.
Nicholson KM and Anderson NG. (2002). Cell Signal., 14, 381-395.
Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, Masuyama N and Gotoh Y. (2002). J. Biol. Chem., 277, 21843-21850.
Ogiso Y, Tomida A, Lei S, Omura S and Tsuruo T. (2000). Cancer Res., 60, 2429-2434.
Plo I, Bettaieb A, Payrastre B, Mansat-De Mas V, Bordier C, Rousse A, Kowalski-Chauvel A, Laurent G and Lautier D. (1999). FEBS Lett., 452, 150-154.
Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B, Priller J, Dirnagi U and Meisel A. (2002). J. Neurosci., 22, 10291-10301.
Sakamuro D, Sabbatini P, White E and Prendergast GC. (1997). Oncogene. 15, 887-898.
Sanna K and Rofstad EK. (1994). Int. J. Cancer, 58, 258-262.
Tanaka M and Grossman HB. (2003). Gene Ther., 10, 1636-1642.
Teicher BA. (1994). Cancer Metast. Rev., 13, 139-168.
Tomida A and Tsuruo T. (1999). Anticancer Drug Des., 14, 169-177.
Vaupel P, Thews O and Hoeckel M. (2001). Med. Oncol., 18, 243-259.
Yamaguchi A, Tamatani M, Matsuzaki H, Namikawa K, Kiyama H, Vitek MP, Mitsuda N and Tohyama M. (2001). J. Biol. Chem., 276, 5256-5264.
Yu J, Wang Z, Kinzler KW, Vogelstein B and Zhang L. (2003). Proc. Natl. Acad. Sci. USA, 100, 1931-1936.